Sterling Capital Management’s iRadimed IRMD Stock Holding History

Sterling Capital Management’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.1K	Sell	53 -3	-5%	-$300	﹤0.01%	2722
2025 Q4	$5.45K	Buy	56 +36	+180%	+$3.09K	﹤0.01%	2867
2025 Q3	$1.42K	Buy	20 +1	+5%	+$67	﹤0.01%	3028
2025 Q2	$1.14K	Buy	19 +10	+111%	+$548	﹤0.01%	3040
2025 Q1	$472	Hold	9	–	–	﹤0.01%	2966
2024 Q4	$495	Buy	9 +2	+29%	+$105	﹤0.01%	3037
2024 Q3	$352	Buy	+7	New	+$323	﹤0.01%	2992

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's IRMD Position: Q1 2026 in Review

Sterling Capital Management reduced its iRadimed (IRMD) stake by 5.4% in Q1 2026, selling an estimated $300 and leaving 53 shares worth $5.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2722.

Sterling Capital Management first reported a position in IRMD in Q3 2024 and has held it in 7 quarters since. The position peaked at $5.45K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Sterling Capital Management held 53 shares of iRadimed worth $5.1K as of Q1 2026.
Sterling Capital Management sold 3 iRadimed shares in Q1 2026, an estimated $300.
iRadimed made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2722 holding.
Sterling Capital Management first reported a position in iRadimed in Q3 2024 and has held it in 7 quarters since.
Sterling Capital Management's iRadimed position peaked at $5.45K in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.